tbuckley/cabot-search huggingface dataset:
MA13.09 Serial FDG and FLT PET/CT during Curative-Intent Chemo-Radiotherapy for NSCLC Impacts Patient Management and May Predict Clinical Outcomes
Authors: David Ball, Sarah Everitt, Rodney Hicks, Jason Callahan, Alan Herschtal, Tomas Kron, Nikki Plumridge, Michael Mac Manus
Journal: Journal of Thoracic Oncology (2017)
Human Herpesvirus 8 K1 Derived Peptides Reduced the Levels of Apoptosis Inhibitory Fas-K1 Complex: A Strategy for Stimulating Death Receptor Mediated Apoptosis.
Authors: Shu Wang, Zuzana Berkova, Suizhao Wang, Jaehoon Jung D. Pharm, Hoyoung Maeng, Felipe Samaniego
Journal: Blood (2007)
<i>Notes from the Field</i>: Compliance with Postexposure Prophylaxis for Exposure to <i>Bacillus anthracis</i> Among U.S. Military Personnel — South Korea, May 2015
Authors: Koya C. Allen, Katherine Hendricks, Eric Sergienko, Raul Mirza, Rohit A. Chitale
Journal: MMWR Morbidity and Mortality Weekly Report (2017)
Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
Authors: Erasmia Vlachou, Shamindra Direkz, Alberto Murino, Peter Wylie, Mark Hamilton, Charles Murray, Edward Despott
Journal: Endoscopy (2017)

A 46-year-old woman presented with small-bowel obstruction (SBO) 2 months after placement of two Obalon gastric balloons (Obalon Therapeutics, California, USA) for weight loss [1]. A computed tomography (CT) scan confirmed SBO caused by a partially deflated balloon that had migrated into the ileum; the other balloon remained inflated and in situ within the stomach ([Fig. 1] and [Fig. 2]).
P1.03-022 Possibility of FDG-PET Predicting the Clinicopathological Characteristics and Prognosis of Lung Adenocarcinoma: Multicenter Study
Authors: Kumi Matsuura, Ken Taro Imai, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda, Haruhiko Nakayama, Hiroyuki Ito, Morihito Okada, Yoshihiro Miyata
Journal: Journal of Thoracic Oncology (2017)
S113 High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis in mongolia: a double-blind randomised controlled trial
Authors: D Ganmaa, B Munkhsul, S Bromage, B Buyankhishig, AR Martineau
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Existing trials of adjunctive vitamin D to enhance response to antimicrobial therapy for pulmonary tuberculosis are variously limited by relatively small sample sizes, inadequate dosing regimens and low baseline prevalence of vitamin D deficiency among participants. Our objective was to conduct a large randomised controlled trial of high-dose vitamin D in a setting where profound vitamin D deficiency was common in patients with pulmonary TB. <h3>Methods</h3> We conducted a double-blind randomised placebo-controlled trial of high-dose adjunctive vitamin D3 in adults with sputum smear-positive pulmonary tuberculosis in Ulaanbaatar, Mongolia. 390 participants were allocated to receive 3.5 mg vitamin D3 (n = 190) or placebo (n = 200) at baseline and at 2, 4 and 6 weeks after starting standard tuberculosis treatment. The primary endpoint of the trial was time from initiation of antimicrobial therapy to sputum culture conversion. Secondary endpoints were time to sputum smear conversion, resolution of infiltrates on chest radiograph and serum 25-hydroxyvitamin D (25[OH]D) concentrations. This trial was registered with ClinicalTrials.gov (NCT01657656). <h3>Results</h3> At baseline, 81% of participants had profound vitamin D deficiency (serum 25[OH]D &lt;25 nmol/L). Vitamin D supplementation elevated 8-week serum 25(OH)D concentrations to high-physiological levels (154.5 in intervention arm vs. 15.2 nmol/L in placebo arm, 95% CI: for difference 125.9 to 154.7 nmol/L, P &lt; 0.001), but did not influence time to sputum culture conversion (adjusted hazard ratio 1.11, 95% CI: 0.88 to 1.39, P = 0.39). Allocation to vitamin D was associated with accelerated sputum smear conversion (adjusted HR 1.47, 95% CI: 1.09 to 1.98, P = 0.01) and a small but statistically significant reduction in the mean number of zones affected on chest radiograph at 8 weeks (5.48 vs. 5.69, 95% CI: for difference 0.06 to 0.77 zones, p = 0.02). <h3>Conclusions</h3> This is the largest randomised controlled trial to investigate effects of adjunctive vitamin D on time to sputum culture conversion in pulmonary tuberculosis conducted to date. Adjunctive high-dose vitamin D was effective in elevating serum 25(OH)D concentrations to high-physiological levels, but did not influence time to sputum culture conversion.
Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?
Authors: Nadine Ajzenberg, Dorothee Faille, Marie-Genevieve Huisse, Anh Hong Cung, Lamia Lamrani, Nicolas Dumontier, Martine Jandrot-Perrus, Bruno Cassinat, Christine Chomienne, Christine Dosquet
Journal: Blood (2014)
PUB118 Pre-Chemotherapy EGFR Mutation Status &amp; Outcomes with Second Line Gefitinib in Advanced Adenocarcinoma Lung
Authors: Ashay Karpe, Vanita Noronha, Vijay Patil, Amit Joshi, Anuradha Chougule, Amit Janu, Sucheta More, Supriya Goud, Anant Ramaswamy, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Kumar Prabhash
Journal: Journal of Thoracic Oncology (2017)
Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents
Authors: Juan J Gu, Qunling Zhang, Cory Mavis, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2015)
Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability
Authors: Yulia A. Komarova, Kevin Kruse, Dolly Mehta, Asrar B. Malik
Journal: Circulation Research (2017)

The monolayer of endothelial cells lining the vessel wall forms a semipermeable barrier (in all tissue except the relatively impermeable blood-brain and inner retinal barriers) that regulates tissue-fluid homeostasis, transport of nutrients, and migration of blood cells across the barrier. Permeability of the endothelial barrier is primarily regulated by a protein complex called adherens junctions. Adherens junctions are not static structures; they are continuously remodeled in response to mechanical and chemical cues in both physiological and pathological settings. Here, we discuss recent insights into the post-translational modifications of junctional proteins and signaling pathways regulating plasticity of adherens junctions and endothelial permeability. We also discuss in the context of what is already known and newly defined signaling pathways that mediate endothelial barrier leakiness (hyperpermeability) that are important in the pathogenesis of cardiovascular and lung diseases and vascular inflammation.
Reduced-Intensity Conditioning for Allografting Following Autografting for Myeloma: Lower Relapse Rates Compared with Single or Double Autografting but Similar Overall Survival. The Genoa Experience in 74 Patients.
Authors: A.M. Carella, G. Catania, S. Biasco, M. Congiu, S. Nati, E. Rossi, R. Vimercati, D. Ciapanna, M. Spriano
Journal: Blood (2007)
OA24.02 Locally Advanced Non-Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA Trial)
Authors: Sara Ramella, Michele Fiore, Sonia Silipigni, Massimo Jaus, Maria Cristina Zappa, Antonio Alberti, Paolo Matteucci, Elisabetta Molfese, Patrizia Cornacchione, Lucio Trodella, Edy Ippolito, Rolando D'Angelillo
Journal: Journal of Thoracic Oncology (2017)
Abstract A28: Targeting the epigenetic state regulating cancer cell vulnerability to proteasome inhibition
Authors: Peter Tsvetkov, Ethan Sokol, Dexter Jin, Piyush Gupta, Sandro Santagata, Luke Whitesell, Susan Lindquist
Journal: Clinical Cancer Research (2017)

Abstract The proteasome is a central regulator of protein homeostasis in all eukaryotes. Targeted pharmaceutical inhibition of the proteasome complex has been implemented as a successful therapeutic strategy to treat several cancers including multiple myeloma. Unfortunately, many of the cancers show intrinsic resistance to proteasome inhibitors, and those that are initially responsive eventually develop resistance by a poorly understood mechanism. We have recently performed genome-wide screens for mutations that allowed cells to survive in the presence of two distinct proteasome inhibitors (bortezomib and MG132). Counter to expectation, we have shown that reducing any one of the many of the subunits of the regulatory cap complex (19S) is sufficient to alter both the levels and ratio of the 26S/20S proteasome complex and induce increased resistance to proteasome inhibition. These findings motivated us to establish a cell-based screening strategy to identify molecules that specifically target the proteasome inhibitor (PI)-resistant state. We further exploited the Genomics of Drug Sensitivity in Cancer (GDSC) database to analyze the efficacy of PIs across 315 cancer cell lines for which we also had matched gene expression data. This analysis revealed that a significant decrease in the gene expression of one component of the 19S complex is both naturally occurring (in almost 6-8% of cells examined) and is sufficient to predict resistance to PIs. We termed these cells, proteasome HYDRA (Hypo expression Yielding Drug Resistance Ability) cancer cells. Further exploring the HYDRA cells utilizing the Cancer Cell Line Encyclopedia (CCLE) dataset revealed that the loss of expression of the proteasome subunit is not associated with a loss of gene copy number but rather is an epigenetic mechanism of reduced gene expression. We show here a novel cellular epigenetic switch utilized by many cancer cells that renders them resistant to proteotoxic stress. Our findings enable prediction of cancer cell vulnerability to proteasome function perturbation and also facilitate the specific targeting of this unique epigenetic state by selective drug treatment. Citation Format: Peter Tsvetkov, Ethan Sokol, Dexter Jin, Piyush Gupta, Sandro Santagata, Luke Whitesell, Susan Lindquist. Targeting the epigenetic state regulating cancer cell vulnerability to proteasome inhibition. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A28.
P140 Comorbidities of swedish patients diagnosed with chronic obstructive pulmonary disease (COPD) and/or asthma
Authors: G Johansson, C Jansen, M Van Der Tol, R Ariely, G Bergman, M Uhde, P Sobocki, H Benhaddi
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Standard of care treatments for asthma and COPD are commonly administered in single-dose or multidose dry powder inhalers. There is a dearth of evidence around the prevalence of comorbidities, especially those that may affect inhaler device handling, among Swedish asthma and COPD patients. <h3>Methods</h3> This retrospective study from the Swedish National Health Registries included 495,254 patients receiving inpatient or specialised outpatient care in Sweden between January 1, 2005 and December 31, 2014. Estimates of severity were based on number of asthma/COPD drugs used. Diagnostic codes were used to assess number of patients with a pre-specified comorbidity potentially affecting device handling. <h3>Results</h3> Patient characteristics, treatments and comorbidities are summarised in the Table. Comorbidities that may impact inhaler handling were observed in 15.8% (asthma), 50.4% (COPD) and 55.3% (asthma/COPD) patients; incidence was increased with disease severity (patients with severe disease: 26.3%, 52.0%, 55.9%) and advanced age (patients 60–69 years: 33.2%, 45.2%, 50.5%, respectively). <h3>Conclusions</h3> Comorbidities potentially affecting device handling were common across all groups, and unexpectedly high among elderly asthma patients. Furthermore, the data indicate that a substantial percentage of patients use two or more separate inhalers. These findings highlight the need for newer, easier to use inhalers, as well as training and monitoring of device use in patients who may have more difficulties using their devices correctly due to comorbidities.
P2.01-052 High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung
Authors: Manuel Keller, Christina Neppl, Yasin Irmak, Sean Hall, Ralph Schmid, Rupert Langer, Sabina Berezowska
Journal: Journal of Thoracic Oncology (2017)
Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome
Authors: Frank G. Rücker, Sibylle Cocciardi, Anna Dolnik, Tamara J. Blätte, Ulrike Wüst, Peter Paschka, Verena I. Gaidzik, Richard F. Schlenk, Hartmut Döhner, Lars Bullinger, Konstanze Döhner
Journal: Blood (2015)
Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.
Authors: Mansoor N Saleh, Gregory Cheng, James B Bussel, Paul Burgess, Kalpana Bakshi, Andres Brainsky, Christine K Bailey
Journal: Blood (2012)
OA24.03 Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy
Authors: Kyle Wang, Michael Eblan, Matthew Lipner, Allison Deal, Timothy Zagar, Carrie Lee, Brian Jensen, Panayiotis Mavroidis, Julian Rosenman, Thomas Stinchcombe, Lawrence Marks
Journal: Journal of Thoracic Oncology (2017)
P1.04-001 EGFR, EML4-ALK, ROS 1 and BRAF Testing in Austrian Patients with NSCLC: A Multicenter Study
Authors: Sophia Holzer, Maximilian Hochmair, Ulrike Setinek, Dagmar Krenbek, Hannah Fabikan, Rosemarie Rumbold, Andrea Mohn-Staudner, Klaus Kirchbacher, Madeleine Arns, Tatjana Bundalo, Kurt Patocka, Otto Burghuber
Journal: Journal of Thoracic Oncology (2017)
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications
Authors: Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Cristina Papayannidis, Gabriele Gugliotta, Francesca Palandri, Hana Klamova, Ilaria Iacobucci, Claudia Venturi, Federica Cattina, Paola Bresciani, Valeria Coluccio, Marzia Salvucci, Mario Tiribelli, Gianni Binotto, Tamara Intermesoli, Mario Luppi, Maria Teresa Bochicchio, Emanuela Ottaviani, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2012)
S15 Changes in perioperative ards with time: a comparison of two trials
Authors: PA Howells, KA Aldridge, RCA Dancer, O Tucker, DR Thickett
Journal: Thorax (2016)

<h3>Introduction and objective</h3> The BALTI-Prevention Trial1 translational sub-study (recruitment completed in 2011) and VINDALOO Trial2 (recruitment completed in 2015) both used oesophagectomy as a model for investigation of the pharmacological prevention of ARDS. The VINDALOO trial showed a lower ARDS incidence independent of the agents evaluated. Our objective was to characterise this difference. <h3>Methods</h3> Databases from both trials were available and additional information was obtained retrospectively from hospital records. Analysis was performed using appropriate statistical tests. <h3>Results</h3> There was a substantially higher ARDS incidence in BALTI-P compared to VINDALOO (RR 1.17 (1.08–1.28)) (Figure 1). There were more never (21 versus 7) and fewer current (12 versus 25) smokers in the VINDALOO group (p = 0.003). Perioperative risk scores did not differ between groups (P-POSSUM mortality p = 0.98, P-POSSUM morbidity p = 0.87, O-POSSUM p = 0.58), nor did use of neoadjuvant chemotherapy (p = 1.0). The incidence of serious complications (Clavien-Dindo score of four or more), was not different between the two groups (RR 1.15 (0.94–1.40)). Univariate analysis of the combined groups showed risk factors for ARDS not using regional anaesthesia (OR 3.2 (1.0–9.8) p = 0.038) and current smoking (OR 3.0 (1.1–8.3) p = 0.038). <h3>Conclusion</h3> Smoking is an environmental risk factor for ARDS and changing patterns in smoking behaviour appear important in these perioperative cohorts. Other studies have demonstrated that aggregates of small but important changes in care can cumulatively make a significant difference to risk of nosocomial ARDS and our data suggests that this may have resulted in a reduction in perioperative ARDS in this group. Our study has demonstrated that ARDS incidence post oesophagectomy has fallen. In future, trials utilising oesophagectomy as a model of ARDS should consider selection of a defined higher-risk sub-set of patients. <h3>References</h3> Perkins G, <i>et al</i>. The beta agonist lung injury trial prevention. A randomised controlled trial. <i>Am J Respir Crit Care Med</i> 2014;1<b>89</b>(6):674–683. Parekh D, <i>et al</i>. Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. <i>Trials</i> 2013;<b>14</b>(100). doi:10.1186/1745-6215-1114-1100.
Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.
Authors: M. MacPartlin, T. O’Hare, T. Bumm, V. Goss, K. Lee, A. Corbin, E.A. Stoffregen, C. Smith, K. Johnson, E. Moseson, I. Griswold, L. Wood, R. Polakiewicz, Brian J. Druker, Michael W.N. Deininger
Journal: Blood (2006)
P3.02c-011 A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors
Authors: Philip Gold, R. Donald Harvey, Alexander Spira, Lyudmila Bazhenova, John Nemunaitis, Joaquina Baranda, Shirish Gadgeel
Journal: Journal of Thoracic Oncology (2017)
P2.01-065 Quantification of Tumor-Immune Cell Spatial Relationships in the Lung Tumor Microenvironment Using Single Cell Profiling
Authors: Katey Enfield, Sonia Kung, Paul Gallagher, Katy Milne, Zhaoyang Chen, Daniela Piga, Stephen Lam, John English, Martial Guillaud, Calum Macaulay, Wan Lam
Journal: Journal of Thoracic Oncology (2017)
Noninvasive evaluation of total occlusion of infarct-related coronary artery after a first myocardial infarction.
Authors: Taishiro Chikamori, Yoshinori Doi, Yoshihiro Yonezawa, Mitsutoshi Yamada, Toshio Ozawa
Journal: Circulation (1993)

Previous studies have demonstrated that the long-term prognosis after acute myocardial infarction in patients whose infarct-related artery remains occluded is worse than that in those with anterograde flow. To determine how to identify patients with occluded infarct-related arteries noninvasively, 143 consecutive patients after a first myocardial infarction underwent exercise testing and dipyridamole thallium scintigraphy. The incidence of total occlusion was higher in inferior/posterior infarction than in anterior infarction (29/53 vs 28/90; p = 0.005). In patients with inferior/posterior infarction, discriminant analysis revealed a sensitivity of 79%, a specificity of 88% and an accuracy of 83% (p=0.0005) in identifying those with an occluded infarct-related artery. In patients with anterior infarction, the analysis showed a sensitivity of 68%, a specificity of 85% and an accuracy of 79% (p<0.0001) in identifying those with an occluded artery. These results indicate that noninvasive study may be useful in the evaluation of total occlusion of the infarct-related coronary artery.
P225 Triggers of vocal cord dysfunction and asthma
Authors: SHK Chua, J Haines, C Slinger, SJ Fowler
Journal: Thorax (2016)

<h3>Background</h3> Vocal cord dysfunction (VCD) is often initially misdiagnosed as, or may coexist with, asthma. Identifying the differences between the types of triggers for each condition may help differentiate between these two conditions, and could give mechanistic insights. <h3>Aim</h3> The aim of this study is to identify and compare patient-reported triggers in VCD and asthma. <h3>Methods</h3> This was a two-part study. <i>Part A</i> – A retrospective case note review of the triggers of VCD from endoscopically-confirmed VCD patients was conducted. This information was used to generate a Breathlessness Triggers Survey with triggers recorded under the categories: scents, environmental factors, temperature, emotions, mechanical factors and daily activities. <i>Part B</i> – A prospective study which involved patients with VCD and/or asthma completing the Breathlessness Triggers Survey, rating the likelihood of each item triggering their symptoms using a five-point Linkert scale (strongly disagree to strongly agree). Chi-square test was performed to compare responses by cohort. <h3>Results</h3> <i>Part A</i> – Data from 202 patients with VCD (73.3% female, mean age 53.1yrs) were included in the retrospective study. The findings were used to create a 23-item Breathlessness Triggers Survey for Part B of the study. <i>Part B</i> – 38 patients with VCD-only (63.2% females, mean age 56.8 yrs), 39 patients with asthma-only (56.4% female, mean age 53.3 yrs) and 12 patients with both VCD and asthma (83.3% female, mean age, 56.8yrs) were recruited. The mean number of patient-reported triggers in the VCD and asthma cohort was 11 and 13 respectively. Mechanical factors such as talking (p ≤ 0.001), shouting (p = 0.004) and swallowing (p ≤ 0.001) were more common in the VCD cohort, whilst environmental factors such as pollen/flowers (p = 0.002) and damp air (p = 0.039) were more common in asthma. There were no differences between groups in frequency of reporting scents as triggers (except for vinegar, more common in VCD), temperature, emotions or daily activities. <h3>Conclusion</h3> There were notable differences and overlaps between patient-reported triggers of VCD and asthma, which could give clues to diagnosis during clinical assessment. Future work should focus on the mechanisms underlying these findings.
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy
Authors: G Cutrona, S Matis, M Colombo, C Massucco, G Baio, F Valdora, L Emionite, S Fabris, A G Recchia, M Gentile, C E Neumaier, D Reverberi, R Massara, S Boccardo, L Basso, S Salvi, F Rosa, M Cilli, S Zupo, M Truini, P Tassone, M Calabrese, M Negrini, A Neri, F Morabito, F Fais, M Ferrarini
Journal: Leukemia (2017)